Calyxo, Inc. — SEC Form D Filing

Calyxo, Inc. filed an SEC Form D on April 16, 2026, reporting $40.10M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
April 16, 2026
Amount reported
$40.10M
Round stage
Seed
Industry
Health Care
Website
https://calyxoinc.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Calyxo addresses the challenges of kidney stone treatment effectiveness and recovery time. Current methods can be invasive and less effective.

Solution

Calyxo provides the CVAC System, which enables the SURE Procedure, a minimally invasive method that improves stone clearance rates and patient outcomes.

Why now

With increasing rates of kidney stones and demand for effective treatments, there is a pressing need for advanced solutions in this area.

Verdict

Investors said yes primarily because the urgency surrounding kidney stone treatment and Calyxo's promise of improved outcomes resonated strongly at the time. They were implicitly betting on the increasing prevalence of kidney stones necessitating innovative solutions, not on a well-defined budget owner or a clear articulation of cost replacement. The limited upside lies in over-reliance on a niche market and insufficient differentiation from established players, which could lead to stagnation rather than sustainable growth.

Source: SEC EDGAR Form D filing